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Abstract 
 
Background: To stratify the outcomes of phacoemulsification combined with trabectome 
surgery (PT) using glaucoma severity index (GI). 
 
Methods: This is a retrospective, observational cohort study performed in the Department of 
Ophthalmology, University of Pittsburgh Medical Center. Inclusion criteria were subjects with 
primary or secondary open angle glaucoma along with a visually significant cataract and the 
need to lower IOP or the number of glaucoma medications. Only cases that had undergone 
trabectome surgery combined with phacoemulsification were included. Exclusion criteria were 
follow-up less than 12 months, any other surgery during this time or diagnosis of neovascular or 
active uveitic glaucoma. The main outcome measures were IOP, medications, and success when 
stratified by GI. This index incorporated preoperative IOP, medications and visual field. Linear 
regression was used to detect the association between GI group with IOP and medication 
reduction at one year. Log-rank was used for survival analysis. 
 
Results: Of 1374 patients, a total of 498 cases of PT with 12 month follow-up were included in 
the study after applying the exclusion criteria. Mean IOP reduction after one year was 2.9±4.4, 
3.6±5.0, 3.9±5.3, and 9.2±7.6 mmHg for GI groups 1 to 4, respectively. Linear regression showed 
patients in a higher GI group had an IOP reduction greater by 1.69±0.2 mmHg than patients in a 
lower GI group. Survival rate at 12 months was 98%, 93%, 96% and 88% for GI groups 1 to 4 
(p<0.05).  
 
Conclusions: A substantial IOP reduction was seen in subjects with more advanced glaucoma 
suggesting that the trabecular meshwork is the primary impediment to outflow and its ablation 
benefits those eyes relatively more than in mild glaucoma. Higher GI groups are expected to 
have a greater reduction of IOP. 
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Introduction 
Cataract and glaucoma are the two main causes of visual impairment worldwide ​[1]​ but while 
vision can be recovered by cataract extraction and intraocular lens implantation, vision loss 
from glaucoma is irreversible. Co-existence of open-angle glaucoma and cataract are frequently 
seen in the elderly population. Incidence and prevalence of both increase with age ​[2]​. Elevated 
IOP and use of glaucoma medications can increase the risk of development of a nuclear cataract 
[3]​. Similarly, glaucoma surgery can also accelerate cataract progression ​[4]​. Removal of 
cataracts can confer a modest IOP reduction and have occasionally been recommended as a 
first intervention towards controlling pressure in glaucoma ​[5–7]​. In countries where access to 
more advanced and more expensive technology exists, phacoemulsification is the most 
frequently performed type of cataract surgery ​[8]​ and produces the better visual results ​[9]​.  
 
Ab interno trabeculectomy (AIT) belongs to the family of microincisional glaucoma surgeries 
[10]​ that are relatively standardized and have a favorable safety profile compared to traditional 
filtering surgeries ​[11]​. AIT lowers IOP by ionizing and disrupting the diseased trabecular 
meshwork and creates a direct pathway for aqueous to exit the anterior chamber ​[10,12]​. 
Depending on the severity of the respective diseases and the additional requirement for 
lowering IOP, phacoemulsification can be combined with trabectome (PT) benefitting the 
patient with fewer procedures and better cost effectiveness compared to long-term use of 
drops or to two separate operating room procedures ​[13]​. Glaucoma can be graded according 
to the visual field function, optic nerve damage, or both ​[14–16]​.  
 
Previous data on AIT with phacoemulsification after a failed trabeculectomy suggested that 
eyes with more advanced glaucoma may experience a larger IOP reduction although this did 
not reach statistical significance ​[17]​. When trabectome surgery is performed as a single 
procedure to lower IOP a bigger pressure decrease can be observed ​[18]​. We recently described 
that the impact of phacoemulsification on IOP reduction is negligible when PT is compared to 
trabectome surgery in eyes that remain phakic ​[19]​. In this study, we analyzed IOP reduction 
from cataract surgery combined with trabectome as a function of a glaucoma index (GI) 
[18,20,21]​. We also stratified outcomes by glaucoma severity based on preoperative IOP, 
number of preoperative medications, and visual field damage. We hypothesized that outcomes 
of PT would be similar regardless of GI. 
Methods 
Data for this retrospective, observational cohort study was collected after approval by the 
Institutional Review Board of the University of Pittsburgh, in accordance with the Declaration of 
Helsinki and the Health Insurance Portability and Accountability Act (IRB# 
REN15100055). Informed consent was not required. Only cases that had undergone trabectome 
surgery combined with phacoemulsification were included. Exclusion criteria was follow up less 
than 12 months, any other surgery during this time or diagnosis of neovascular or active uveitic 
glaucoma. For each patient, a specific target IOP was established by the treating glaucoma 
specialist deemed to prevent further nerve damage.  
The indications for PT consisted of IOP above target with progressive glaucoma on maximally 
tolerated medical therapy, or stable glaucoma with the need to decrease the number of 
medications and a visually significant cataract with at least 0.4 logMAR (20/50 Snellen) visual 
acuity testing. AIT was completed before same session phacoemulsification in phaco-AIT ​[10]​. 
The visual acuity was expressed as the logarithm of the minimum angle of resolution (logMAR). 
Based on the most recent Humphrey visual field exam (Carl Zeiss Meditec, AG, Jena, Germany), 
visual fields were grouped into four categories of up to mild, up to moderate, up to advanced, 
and more than advanced visual field damage ​[22]​, and designated 1, 2, 3 and 4 points, 
respectively. All patients received a comprehensive slit lamp and ophthalmoscopy exam before 
surgery. Anterior chamber angles in all patients were graded by Shaffer grade (SG) ​[23,24]​, a 
classification system in which ‘0’ to ‘slit’ represents a totally or partially closed angle with 
potential for angle closure that is present or very likely, ‘1’ an angle width of 10° (very narrow) 
and closure potential that is probable, ‘2’ representing 20° and possible potential for closure, ‘3’ 
standing for 20° to 45° with unlikely closure and grade ‘4’ indicating a wide open angle and 
improbable potential for angle closure. 
GI was defined using the following variables: 1) Preoperative IOP, 2) numbers of medications 
used prior to surgery, 3) visual field status. Visual field was separated into four categories: mild, 
moderate, advanced and end stage where mild was assigned 1 point, moderate with 2, 
advanced with 3 and end stage with 4. Preoperative number of medications were divided into 4 
categories: 0-1, 2, 3 or 4+, and assigned with a value of 1 to 4, respectively. Baseline IOP was 
divided into 3 categories: <20 mmHg, 20-29 mmHg, and greater than 30 mmHg and assigned 
with 1 to 3 points respectively. These categories were chosen based on IOP distribution and 
designed​ ​not to underrate low pressure glaucoma and to include the small number of eyes with 
a baseline IOP above 40. GI was then defined as preoperative IOP ⨉ preoperative number of 
medications ⨉ VF. GI was separated into 4 groups: <3 (group 1), 3-5 (group 2), 6-11 (group 3) 
and >12 (group 4). Linear regression was used to determine if there was an association 
between GI group and IOP reduction after one year. 
Baseline characteristics were compared by the Kruskal-Wallis and chi square tests for 
continuous and categorical variables between GI groups, respectively. Univariate linear 
regression was performed first and those variables that were found to be statistically significant 
were included into multivariate regression. Success was defined as IOP≤21 mmHg, at least 20% 
IOP reduction from baseline in any two consecutive visits after three months, and no secondary 
glaucoma surgery. Log-rank test was used to compare survival distributions of GI groups. 
Continuous data was reported as mean ± standard deviation. 
Results 
Of 1374 patients, a total of 498 cases of phaco-AIT were included in the study after applying the 
exclusion criteria. The average age of the patients was ​73±10 ​years. The average preoperative 
IOP was ​20.6±6.6 ​mmHg and the average number of preoperative medications used was 
2.4±1.1.​ The percentage of cases with mild, moderate and advanced visual field status were 
33%, 33%, 34% respectively. The demographics table does not show any significant differences 
in age among the GI groups (Table 1). 
The patient distribution across GI groups was relatively even and only reached a significant 
difference in visual acuity and cup disc ratio (Table 1). Most patients were Caucasian, followed 
by Asians, and then by African Americans and Hispanics. Amongst the GI groups, the majority of 
the patients had the diagnosis of primary open angle glaucoma with Shaffer grade above 2 
followed by pseudoexfoliative glaucoma. Pigmentary and steroid induced glaucoma were 
amongst the least common diagnosis. PEX and steroid induced glaucoma patients had a greater 
IOP reduction by 3.75±0.79, 4.27±1.25 mmHg than OAG patients. The cup to disc (C/D) ratio 
increased significantly from a mean of 0.66 to 0.81 from GI1 to GI4. In contrast, visual acuity 
showed a significant decrease from GI1 to GI4 with GI4 nearly half of that of GI1.  
At the end of 12 months, visual acuity showed a significant improvement for all the GI groups 
(Table 2). 
Most patients had a preoperative IOP below 20 mmHg and most of them used three drops to 
achieve that (Figure 1). The visual field damage was relatively evenly distributed among mild, 
moderate and advanced damage. There were no patients with end stage visual fields (Figure 1).  
At one year, glaucoma index groups 1 through 3 had an IOP reduction of about 4 mmHg in 
average while group 4, with the most advanced glaucomas, had a reduction near 10 mmHg 
(Figure 2).  
Univariate linear regression (Table 3), which was performed first, identified age, diagnosis of 
pigmentary glaucoma and steroid induced glaucoma, and visual acuity to be most significant. 
These variables were then included in the multivariate regression.  
In the multivariate regression analysis (Table 4), GI group, the diagnosis of pseudoexfoliation 
glaucoma and steroid induced glaucoma, were found to be significantly associated with IOP 
reduction. We examined the glaucoma index variables and their individual relationships to 
postoperative IOPs at the different time points.  Patients in a higher glaucoma index group had 
a larger absolute IOP decrease (Figure 3). While there was an overall decrease in the number of 
medications in all glaucoma index groups (GI), GI3 and GI4 showed the most significant changes 
(p<0.05) after 6 months postoperatively (Figure 4). Individuals with more advanced visual field 
damage had the largest IOP reduction (Figure 5). Kaplan-Meier survival rate at 12 months was 
98%, 93%, 96% and 88% for GI group 1 to 4.​ ​Log-rank test suggested a significant difference in 
survival distributions between GI groups. Patients in lower GI groups had a higher survival rate 
than those in the highest GI group (Figure 6). 
Discussion 
In this study, we stratified the outcomes of PT by a glaucoma index and found that there is a 
modest correlation to the severity of open angle glaucoma indicating that a larger IOP 
reduction is achieved in more severe glaucoma. Phacoemulsification on its own can produce a 
small but significant pressure drop by 1.5 to 3 mmHg and eyes with higher preoperative IOP 
often a greater reduction ​[25,26]​. This effect may be the result of a trabeculoplasty-like effect 
[27,28]​, brought on by a stress response ​[29]​ or at other times due to a resolved phacomorphic 
component ​[30]​. On the other hand, it is not uncommon for glaucoma patients who already 
have a compromised trabecular meshwork to experience pressure spikes after cataract surgery 
[31,32]​; those can be prevented by combining trabecular ablation with cataract surgery ​[33]​. 
Combining phacoemulsification with AIT has many advantages that include functional vision 
improvement, reduction of cost and efforts and good safety ​[11]​.  
 
In the case of pseudoexfoliation, removing the cataractous lens also reduces production of 
pseudoexfoliation material ​[34]​ that may produce obstruction of the collector openings. It is for 
these reasons that patients examined here have a fundamentally different indication compared 
to patients who undergo trabectome surgery for the sole purpose of IOP reduction ​[18]​. It is 
therefore not surprising that the regression analysis in the current study only agrees with our 
prior study on secondary, steroid induced glaucoma and age as significantly correlated.​ The 
average age of the patients displayed the increased incidence of cataract with advancing age ​[1] 
which is also a risk factor for glaucoma ​[35]​. The percentage of patients with cataract were 
equally distributed amongst the different GI groups. ​Pseudoexfoliation can cause both earlier 
and more severe cataracts and may also lead to glaucoma. Pseudoexfoliation was significant in 
the present multivariate analysis but not in the prior, trabectome-only, study ​[18]​. 
Pseudoexfoliation glaucoma is often more aggressive than primary open angle glaucoma and 
experiences a more profound IOP reduction ​[36]​. It is therefore fitting that such patients were 
found more commonly in the higher GI group and had greater reduction of IOP following PT. 
Interestingly, pigment dispersion glaucoma is also seen to be significantly correlated here but 
not in the prior trabectome-only study. The reason for this observation is most likely that such 
patients often have a reverse pupillary block and friction between ciliary processes, the 
posterior iris and the crystalline lens and may undergo cataract surgery ​[37]​ sooner than other 
patients. Outcomes of trabectome surgery in pigment dispersion syndrome are otherwise 
relatively similar to outcomes in primary open angle glaucoma ​[38]​.  
 
We found that patients in a GI group higher had an IOP reduction that was better by 1.69±0.24 
mmHg. As could be expected, this is less than the 2.98±0.28 mmHg in trabectome-only patients 
[18]​. There was an overall decrease in the number of medications in all the groups but GI3 and 
GI4 showed the largest change at 12 months. We had previously applied a vigorous statistical 
matching method, Coarsened Exact Matching, which makes up for the shortcomings of 
nonrandomized studies and found that the impact of cataract surgery on IOP reduction in 
combination with cataract surgery is negligible ​[19]​. The results here are consistent with this 
and indicate that, contrary to common believe, cataract removal does not confer any additional 
IOP reduction in ab interno trabeculectomy.  
Conclusions 
In conclusion, PT had a mixed indication of a visually significant cataract and​ ​ the need to lower 
IOP ​or ​ an interest in reducing the number of glaucoma medications. Despite a less absolute 
indication to lower IOP, a substantial pressure reduction was seen in patients with more 
advanced glaucoma which suggests that the trabecular meshwork is the primary impediment to 
outflow. The ablation benefits eyes with more challenging glaucoma relatively more than those 
with mild disease.​ ​Although patients with advanced glaucoma had a slightly lower success rate, 
PT does appear to make for a reasonable first line of treatment and is recommendable over 
phacoemulsification alone for visually significant cataracts. 
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Figure legends 
 
Figure 1. Distribution of glaucoma index variables.  
Most patients had a preoperative intraocular pressure in the range below 20 mmHg. Three 
medications was the most common median number of eye drops used. Visual field score 
distribution was even and included a relatively large number of eyes with advanced visual field 
damage. 
†​IOP: Intraocular pressure  
Figure 2. IOP reduction at one year by glaucoma index group.  
The largest IOP reduction was observed in GI 4 with more severe glaucoma. 
†​GI = Glaucoma Index, ​‡​IOP: Intraocular pressure  
 
Figure 3. Individual IOPs by glaucoma index group.  
Patients in a higher glaucoma index (GI) group had a larger absolute reduction of IOP (table: 
mean±SD). 
†​GI = Glaucoma Index, ​‡​IOP: Intraocular pressure​, ​§​D: Day, ​¶​M: Month 
 
Figure 4. Mean number of medications by glaucoma index group.  
While there was an overall decrease in the number of medications in all glaucoma index groups 
(GI), GI3 and GI4 showed the most significant changes (p<0.05) after 6 months postoperatively. 
†​GI = Glaucoma Index, ​‡​IOP: Intraocular pressure​, ​§​D: Day, ​¶​M: Month  
Figure 5. Intraocular pressure by visual field.  
Patients with advanced visual field damage had the lowest intraocular pressures starting at 1 
month. 
†​GI = Glaucoma Index, ​‡​IOP: Intraocular pressure​, ​§​D: Day, ​¶​M: Month 
 
Figure 6. Survival plot by glaucoma index group.  
Subjects had relatively similar survival rates. 
†​GI = Glaucoma Index 
 
 
  
Tables 
Table 1. Demographics. ​Group 1: GI<3; group 2: 3≤GI<6; group 3: 6≤GI<12; group 4: GI≥12 
 Group 1 n=103 
Group 2 
n=101 
Group 3 
n=168 
Group 4 
n=126 
p-valu
e 
Age     0.33 
   Mean±SD 73±10 72±10 72±10 74±10  
   Range 16 - 90 36 - 91 27 - 90 50 - 93  
Gender     0.42 
   Female 65 (63%) 58 (57%) 85 (51%) 75 (60%)  
   Male 37 (36%) 43 (43%) 81 (48%) 49 (39%)  
   Undocumented 1 (1%) 0 (0%) 2 (1%) 2 (2%)  
Race     0.08 
   African American 9 (9%) 5 (5%) 7 (4%) 4 (3%)  
   Asian 29 (28%) 43 (43%) 61 (36%) 50 (40%)  
   Caucasian 61 (59%) 49 (49%) 83 (49%) 63 (50%)  
   Hispanic 1 (1%) 0 (0%) 2 (1%) 4 (3%)  
   Other 3 (3%) 4 (4%) 15 (9%) 5 (4%)  
Diagnosis     0.19 
   POAG 77 (75%) 75 (74%) 121 (72%) 89 (71%)  
   Pseudoexfoliation Glaucoma 10 (10%) 8 (8%) 24 (14%) 25 (20%)  
   Pigment Dispersion 4 (4%) 5 (5%) 6 (4%) 1 (1%)  
   Steroid induced Glaucoma 4 (4%) 3 (3%) 9 (5%) 6 (5%)  
   Others 8 (8%) 10 (10%) 8 (5%) 5 (4%)  
Visual Acuity (logMAR)     0.01* 
   Mean±SD 0.34±0.31 0.41±0.36 0.35±0.35 0.54±0.62  
   Range 0.00 - 2.00 
-0.19 - 
2.00 
-0.19 - 
2.00 
-0.19 - 
3.00  
Disc Cup/Disk     <0.01* 
   Mean±SD 0.66±0.17 0.70±0.19 0.75±0.15 0.81±0.14  
   Range 0.1 - 0.99 0.2 - 1.0 0.4 - 1.0 0.25 - 1.0  
Shaffer Grade     0.8 
   I 2 (2%) 2 (2%) 0 (0%) 2 (2%)  
   II 9 (9%) 5 (5%) 18 (11%) 14 (11%)  
   III 32 (31%) 33 (33%) 60 (36%) 38 (30%)  
   IV 46 (45%) 47 (47%) 66 (39%) 55 (44%)  
   Undocumented 14 (14%) 14 (14%) 24 (14%) 17 (13%)  
 
†​GI = Glaucoma Index, ​‡​POAG = Primary Open-Angle Glaucoma 
*p<0.05 
 
Table 2. Visual acuity (logMar) at baseline and after phaco-trabectome surgery. 
  GI1 GI2 GI3 GI4 
 ​Baseline  0.34±0.31 0.41±0.36 0.35±0.35 0.54±0.62 
 12 Month 0.11±0.17 0.09±0.19 0.16±0.26 0.27±0.46 
 ​p-value  p<0.01* p<0.01* p<0.01* p<0.01* 
 
†​GI = Glaucoma Index 
*p<0.05 
 
     
     
     
     
     
     
 
 
 
 
 
 
 
 
 
 
Table 3. Univariate regression result. 
 
 Coefficient Standard Error p-value 
Age 0.06 0.03 0.03* 
Male -0.08  0.60  0.90 
Race    
   Asian  1.26  1.33  0.34 
   Caucasian -0.21  1.31  0.87 
   Hispanic  3.88  2.65  0.14 
   Other  0.50  1.73  0.77 
Diagnosis    
   Others  0.00  1.12  1.00 
   Pseudoexfoliation Glaucoma -1.72  1.57  0.27 
   Pigmentary Dispersion  4.52  0.82 <0.01* 
   Steroid Induced Glaucoma  4.25  1.32 <0.01* 
Cup/Disk Ratio 1.33 1.76 0.43 
Visual Acuity (logMAR) 1.96 0.75 0.01* 
Shaffer Grade 0.31 0.39 0.42 
 
*p<0.05 
 
 
  
Table 4. Multivariate regression result. 
 
 Coefficient Standard Error p-value 
GI Group  1.69  0.24 <0.01* 
Age  0.05  0.03  0.08 
Diagnosis    
   Other  0.47  1.06  0.66 
   Pigmentary Dispersion -0.64  1.51  0.67 
   Pseudoexfoliation Glaucoma  3.75  0.79 <0.01* 
   Steroid Induced Glaucoma  4.27  1.25 <0.01* 
Visual Acuity (logMAR)  1.32  0.69  0.06 
 
†​GI = Glaucoma Index 
*p<0.05 
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